Oral contraceptives in systemic lupus erythematosus - A tough pill to swallow?

New England Journal of Medicine

Volumn 353, Issue 24, 2005, Pages 2602-2604

  Bermas, Bonnie L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY;

BIRTH CONTROL; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE EXACERBATION; EDITORIAL; HORMONE SUBSTITUTION; HUMAN; MEDICAL PRACTICE; ORAL CONTRACEPTION; OSTEOLYSIS; OVARY FUNCTION; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; SAFETY; SOCIAL ASPECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

CONTRACEPTIVES, ORAL; FEMALE; HUMANS; LEVONORGESTREL; LUPUS ERYTHEMATOSUS, SYSTEMIC; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 28944441800     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058269     Document Type: Editorial

References (15)

1. Tyrer L. Introduction of the pill and its impact. Contraception 1999;59:Suppl:11S-16S.
2. Junod SW. FDA's approval of the first oral contraceptive, Enovid. In: Making history. Update. Washington, D.C.: Food and Drug Law Institute, 1998.
3. Lahita RG. Emerging concepts for sexual predilection in the disease systemic lupus erythematosus. Ann N Y Acad Sci 1999;876:64-9.
4. Roubinian J, Talal N, Siiteri PK, Sakakian JA. Sex hormone modulation of autoimmunity in NAB/NZW mice. Arthritis Rheum 1979;22:1162-9.
5. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siitieri PK. Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest 1979;63:902-11.
6. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
7. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539-49.
8. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982;25:618-23.
9. Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991;20:427-33.
10. Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997;40:804-8.
11. Buyon JP, Kalunian KC, Skovron ML, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol 1995;1:205-12.
12. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
13. Clowse MEB, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.
14. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 1999;8:3-10.
15. Askanase AD, Buyon JP. Reproductive health in SLE. Best Pract Res Clin Rheumatol 2002;16:265-80.